EULAR & OARSI 2022 Presentations

AKLRD’s data on APPA’s Phase IIa Human Clinical Trial, ‘The Efficacy & Safety of APPA in Symptomatic Knee Osteoarthritis’, was presented as a scientific abstract and as a poster at the congress for European Alliance of Associations for Rheumatology (EULAR) 2022. The data was also presented as a poster at the 2022 OARSI World Congress […]

Read More

Senescence Research in APPA with INIBIC

AKLRD has agreed a further collaboration with the Institute of Biomedical Research of A Coruña (INIBIC) to advance the understanding of APPA’s mechanism of action.  INIBIC is Spain’s leading biomedical research institution. Previous research at INIBIC has shown that APPA has a significant effect on senescent cells in human chondrocytes1 – see BMJ abstract. This […]

Read More

Completion of Phase 2a Human Trial

AKL Research and Development (AKLRD) has recently completed a Phase 2a, 28-day 150 patient, trial of oral APPA in osteoarthritis (OA) of the knee The data from this Phase 2a trial adds considerably to our understanding of APPA. It advances our ability to select the patients most likely to benefit from APPA. Key Findings from […]

Read More

MHRA awards Innovation Passport for APPA in Osteoarthritis

Following consideration by MHRA, NICE, and SMC, the Innovative Licensing and Access Pathway Steering Group has informed AKL Research & Development Ltd that the innovative medicine designation, the Innovation Passport, has been awarded for APPA in the treatment of osteoarthritis. The Innovation Passport is the entry point to the Innovative Licensing and Access Pathway (ILAP) […]

Read More